Frazier Life Sciences Management, L.P. Krystal Biotech, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 788,460 shares of KRYS stock, worth $139 Million. This represents 7.41% of its overall portfolio holdings.
Number of Shares
788,460
Previous 988,460
20.23%
Holding current value
$139 Million
Previous $180 Million
31.28%
% of portfolio
7.41%
Previous 9.67%
Shares
8 transactions
Others Institutions Holding KRYS
# of Institutions
299Shares Held
24.3MCall Options Held
388KPut Options Held
233K-
Black Rock Inc. New York, NY3.95MShares$696 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$508 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$464 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$226 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$155 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.53B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...